AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7829793 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery between 24 hours and 42 days after entry
Number of subjects: 3339
Study 7829793 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients undergoing bypass surgery
Number of subjects: 3339
Study 2100368 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide diuretics
Number of subjects: 0
Study 2100368 — intervention group
Group type: COMPARATOR
Intervention: Selective beta-blocker
Number of subjects: 0
Study 7001971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornithine salts of branched‐chain ketoacids (34 mmol/d)
Number of subjects: 8
Study 7001971 — intervention group
Group type: COMPARATOR
Intervention: Branched‐chain amino acids (68 mmol/d)
Number of subjects: 8
Study 7001971 — intervention group
Group type: COMPARATOR
Intervention: Calcium salts of branched‐chain ketoacids (34 mmol/d)
Number of subjects: 8
Study 7001971 — intervention group
Group type: COMPARATOR
Intervention: Ornithine alpha‐ketoglutarate (daily dose containing the same quantity of ornithine)
Number of subjects: 8
Study 31634678 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Self-Help plus usual care
Number of subjects: 53
Study 31634678 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 53
Study 31599245 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 260
Study 31599245 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 260
Study 26651852 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 32
Study 26651852 — intervention group
Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 32
Study 25567214 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 500 mg + Zolpidem 10 mg
Number of subjects: 40
Study 25567214 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin 500 mg
Number of subjects: 40
Study 25567214 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem 10 mg
Number of subjects: 40
Study 23832430 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 408
Study 23832430 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 408
Study 20874769 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochloride pioglitazone (DP group)
Number of subjects: 98
Study 20874769 — intervention group
Group type: COMPARATOR
Intervention: Sulphonylurea (DS group)
Number of subjects: 98
Study 20874769 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (group NC)
Number of subjects: 98
Study 18246854 — intervention group
Group type: EXPERIMENTAL
Intervention: Ericksonian therapy using hypnosis (ET)
Number of subjects: 0
Study 18246854 — intervention group
Group type: COMPARATOR
Intervention: Brief dynamic therapy (BDT)
Number of subjects: 0
Study 16368316 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 70
Study 16368316 — intervention group
Group type: COMPARATOR
Intervention: Conventional Medical Care (Control)
Number of subjects: 70
Study 12884985 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-chloro-m-cresol 75 micromol L(‐1)
Number of subjects: 352
Study 11208254 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic interventions targeting the RAAS and sympathetic nervous system
Number of subjects: 0
Study 11208254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9231315 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.3 and 0.5/0.6 mg/kg daily for a minimum of 1 week)
Number of subjects: 76
Study 9231315 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled, double-blind crossover protocol
Number of subjects: 76
Study 9231315 — intervention group
Group type: COMPARATOR
Intervention: Community-based child psychiatry outpatient service (open evaluation)
Number of subjects: 76
Study 1461956 — intervention group
Group type: EXPERIMENTAL
Intervention: Low response probability to one standard nonselected number (target)
Number of subjects: 0
Study 1461956 — intervention group
Group type: EXPERIMENTAL
Intervention: High response probability to seven standard nonselected numbers (targets)
Number of subjects: 0
Study 3919171 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V alone for 10 days
Number of subjects: 79
Study 3919171 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin for 10 days with rifampin during the last 4 days
Number of subjects: 79
Study 3919171 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (penicillin alone and penicillin with rifampin)
Number of subjects: 79
Study 30694338 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy plus bid S. boulardii 250 mg
Number of subjects: 199
Study 30694338 — intervention group
Group type: COMPARATOR
Intervention: Standard sequential therapy of bid omeprazole 20 mg plus amoxicillin 1 g for 5 days, followed by bid omeprazole 20 mg, clarithromycin 500 mg and metronidazole 500 mg
Number of subjects: 199
Study 29253512 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of living apart (self and relationship interests do not align)
Number of subjects: 0
Study 29253512 — intervention group
Group type: COMPARATOR
Intervention: Discussion of living together (self and relationship interests do align)
Number of subjects: 0
Study 29253512 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater cardiovascular indexes of threat (regardless of conversation topic)
Number of subjects: 0
Study 27327185 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured self-monitoring of blood glucose (SMBG) for 12 months
Number of subjects: 1024
Study 27327185 — intervention group
Group type: COMPARATOR
Intervention: Control group (active control)
Number of subjects: 1024
Study 24991886 — intervention group
Group type: EXPERIMENTAL
Intervention: audio-drama edutainment intervention
Number of subjects: 106
Study 21947428 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AE)
Number of subjects: 22
Study 21947428 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RT)
Number of subjects: 22
Study 20469809 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 30
Study 20469809 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention (PC)
Number of subjects: 30
Study 17879541 — intervention group
Group type: EXPERIMENTAL
Intervention: SQFZI combined with chemotherapy (docetaxel, flurouracil, calcium folinate)
Number of subjects: 60
Study 17879541 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (control group)
Number of subjects: 60
Study 17879541 — intervention group
Group type: EXPERIMENTAL
Intervention: SQFZI combined with chemotherapy
Number of subjects: 60
Study 17457123 — intervention group
Group type: EXPERIMENTAL
Intervention: Microemulsion propofol (Aquafol; 2 mg/kg bolus followed by variable rate infusion for 60 min)
Number of subjects: 31
Study 17457123 — intervention group
Group type: COMPARATOR
Intervention: Lipid emulsion propofol (Diprivan; 2 mg/kg bolus followed by variable rate infusion for 60 min)
Number of subjects: 31
Study 15114906 — intervention group
Group type: EXPERIMENTAL
Intervention: Placing the encoding question after the target stimulus in explicit memory tasks
Number of subjects: 0
Study 15114906 — intervention group
Group type: COMPARATOR
Intervention: Standard shallow encoding tasks
Number of subjects: 0
Study 10789325 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n = 36) underwent four, monthly 25% drug reduction stages
Number of subjects: 56
Study 10789325 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 20) with no planned drug changes
Number of subjects: 56
Study 10789325 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n = 36) undergoing drug reduction
Number of subjects: 56
Study 9149200 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP infusion (2, 4, and 6 pmol/kg.min for 15 min each)
Number of subjects: 8
Study 9149200 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three periods of 15 min each)
Number of subjects: 8
Study 8397837 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Precision Full Head soft toothbrush
Number of subjects: 75
Study 8397837 — intervention group
Group type: COMPARATOR
Intervention: Oral-B 40 toothbrush
Number of subjects: 75
Study 8397837 — intervention group
Group type: COMPARATOR
Intervention: Reach Full-Head soft toothbrush
Number of subjects: 75
Study 3093667 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitro-Dur
Number of subjects: 24
Study 3093667 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitro-Dur II
Number of subjects: 24
Study 30946077 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Repair with Inferior Mesenteric Artery (IMA) Embolization
Number of subjects: 106
Study 30946077 — intervention group
Group type: COMPARATOR
Intervention: Endovascular Aneurysm Repair without IMA Embolization (Control)
Number of subjects: 106
Study 30946077 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Repair with IMA Embolization
Number of subjects: 106
Study 31161361 — intervention group
Group type: EXPERIMENTAL
Intervention: Local desmopressin (10 μg) administered as a single puff in each side of the nasal cavity 30 minutes before surgery
Number of subjects: 90
Study 31161361 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 90
Study 31161361 — intervention group
Group type: EXPERIMENTAL
Intervention: Local desmopressin
Number of subjects: 90
Study 29624269 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% Cladophora SFE extract in emulsion
Number of subjects: 0
Study 29624269 — intervention group
Group type: COMPARATOR
Intervention: Placebo emulsion
Number of subjects: 0
Study 26979520 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg twice daily in combination with dipyridamole slow-release 200 mg twice daily
Number of subjects: 18
Study 26979520 — intervention group
Group type: COMPARATOR
Intervention: Metformin 500 mg twice daily alone
Number of subjects: 18
Study 24016684 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine
Number of subjects: 30
Study 24016684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22344611 — intervention group
Group type: EXPERIMENTAL
Intervention: DST (automated decision support tool)
Number of subjects: 288
Study 22344611 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD (educational DVD)
Number of subjects: 288
Study 22344611 — intervention group
Group type: EXPERIMENTAL
Intervention: DST+DVD (both DST and educational DVD)
Number of subjects: 288
Study 22344611 — intervention group
Group type: COMPARATOR
Intervention: STG (structured SMBG alone)
Number of subjects: 288
Study 19960983 — intervention group
Group type: EXPERIMENTAL
Intervention: Renshen Jianxin Capsule (RJC)
Number of subjects: 80
Study 19960983 — intervention group
Group type: COMPARATOR
Intervention: Metformin (Control)
Number of subjects: 80
Study 17307761 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised 12 week group exercise programme
Number of subjects: 203
Study 17307761 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 203
Study 15289797 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine 6-12 mg/day
Number of subjects: 367
Study 15289797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 367
Study 11135086 — intervention group
Group type: EXPERIMENTAL
Intervention: L-folinic acid (FNA) 20 mg/day
Number of subjects: 48
Study 11135086 — intervention group
Group type: COMPARATOR
Intervention: Folic acid (FA) 15 mg/day
Number of subjects: 48
Study 9853274 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 80 mg o.d.
Number of subjects: 20
Study 9853274 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril 20 mg o.d.
Number of subjects: 20
Study 9853274 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 80 mg o.d. + indomethacin 50 mg bid
Number of subjects: 20
Study 9853274 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril 20 mg o.d. + indomethacin 50 mg bid
Number of subjects: 20
Study 8037389 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine 25 mg rectal suppository
Number of subjects: 0
Study 8037389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3182519 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO (Carbohydrate ingestion)
Number of subjects: 5
Study 3182519 — intervention group
Group type: COMPARATOR
Intervention: CON (Sweet placebo)
Number of subjects: 5
Study 31852749 — intervention group
Group type: EXPERIMENTAL
Intervention: 2×10^6/kg BM-MNC injection
Number of subjects: 24
Study 31852749 — intervention group
Group type: EXPERIMENTAL
Intervention: 5×10^6/kg BM-MNC injection
Number of subjects: 24
Study 31852749 — intervention group
Group type: COMPARATOR
Intervention: BM-MNC non-treated (Control)
Number of subjects: 24
Study 29660034 — intervention group
Group type: COMPARATOR
Intervention: Control group (Arm 3)
Number of subjects: 210
Study 28486474 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically lowered 25-hydroxyvitamin D (25OHD) levels
Number of subjects: 146761
Study 25408331 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin 10 µg/kg/day
Number of subjects: 32
Study 25408331 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin 30 µg/kg/day
Number of subjects: 32
Study 25408331 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin 100 µg/kg/day
Number of subjects: 32
Study 25408331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 25408331 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin 30 µg/kg/day (Caucasian cohort)
Number of subjects: 32
Study 23278466 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoconstrictor (somatostatin or terlipressin infusion)
Number of subjects: 118
Study 23278466 — intervention group
Group type: COMPARATOR
Intervention: Proton Pump Inhibitor (omeprazole or pantoprazole infusion)
Number of subjects: 118
Study 20541832 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily training plus usual care
Number of subjects: 53
Study 20541832 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 53
Study 20541832 — intervention group
Group type: COMPARATOR
Intervention: Both groups (intervention and control)
Number of subjects: 53
Study 19471252 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) maintenance therapy
Number of subjects: 425
Study 19471252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 425
Study 17461851 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC114/ritonavir (TMC114/r) 600/100 mg twice a day
Number of subjects: 0
Study 17461851 — intervention group
Group type: COMPARATOR
Intervention: Control protease inhibitor (CPI)
Number of subjects: 0
Study 15141519 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapartum antibiotic prophylaxis with Penicillin G or Clindamycin for GBS carriers (161 out of 754 newborns, 21.4%)
Number of subjects: 3023
Study 15141519 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 3023
Study 15187512 — intervention group
Group type: EXPERIMENTAL
Intervention: h‐ANP (50 ng.kg(‐1).min(‐1))
Number of subjects: 61
Study 15187512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 11097098 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Information Routine (EIR)
Number of subjects: 20
Study 11097098 — intervention group
Group type: COMPARATOR
Intervention: Standard information from the specialist clinics
Number of subjects: 20
Study 9350301 — intervention group
Group type: EXPERIMENTAL
Intervention: MKP culture
Number of subjects: 758
Study 9350301 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR
Number of subjects: 758
Study 9350301 — intervention group
Group type: EXPERIMENTAL
Intervention: BSK II culture
Number of subjects: 758
Study 9350301 — intervention group
Group type: EXPERIMENTAL
Intervention: All methods combined
Number of subjects: 758
Study 1440744 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention (18 therapy appointments over one year, including one home visit)
Number of subjects: 126
Study 1440744 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 126
Study 3770386 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscous lidocaine gargle (2%) diluted with tap water (39 ml + 15 ml)
Number of subjects: 90
Study 3770386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 3770386 — intervention group
Group type: COMPARATOR
Intervention: No treatment (neither viscous lidocaine nor placebo)
Number of subjects: 90
Study 31081373 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming training program for 8 weeks
Number of subjects: 33
Study 30337746 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D1 (10 mL of 0.375% ropivacaine + dexmedetomidine 0.2 μg/(kg×h))
Number of subjects: 90
Study 30337746 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D2 (10 mL of 0.375% ropivacaine + dexmedetomidine 0.7 μg/(kg×h))
Number of subjects: 90
Study 30337746 — intervention group
Group type: COMPARATOR
Intervention: Group R (10 mL of 0.375% ropivacaine)
Number of subjects: 90
Study 27588959 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT/LV (uracil‐tegafur and leucovorin)
Number of subjects: 180
Study 27588959 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 180
Study 27588959 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT/LV
Number of subjects: 180
Study 25084042 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal over the right with cathodal over the left DLPFC
Number of subjects: 13
Study 25084042 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal over the right with anodal over the left DLPFC
Number of subjects: 13
Study 25084042 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 13
Study 25084042 — intervention group
Group type: EXPERIMENTAL
Intervention: Right cathodal/left cathodal DLPFC
Number of subjects: 13
Study 24446539 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Number of subjects: 254
Study 24446539 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 254
Study 24446539 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 254
Study 24446539 — intervention group
Group type: COMPARATOR
Intervention: Control (Aripiprazole and Ziprasidone)
Number of subjects: 254
Study 24446539 — intervention group
Group type: COMPARATOR
Intervention: Control (Paliperidone and Ziprasidone)
Number of subjects: 254
Study 24446539 — intervention group
Group type: COMPARATOR
Intervention: Control (Paliperidone and Aripiprazole)
Number of subjects: 254
Study 20691837 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital readmission or death at 30 days
Number of subjects: 614
Study 20691837 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital readmission or death at 90 days
Number of subjects: 614
Study 20691837 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for hospitalization at 30 days
Number of subjects: 614
Study 20691837 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of readmission or death at 30 days
Number of subjects: 614
Study 20691837 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of readmission or death at 90 days
Number of subjects: 614
Study 18292286 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP-like regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 157
Study 18292286 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive regimen
Number of subjects: 157
Study 18292286 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 157
Study 18292286 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediastinal lymphadenopathy
Number of subjects: 157
Study 18292286 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 157
Study 18292286 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in large cells and high level of CD10 and CXCL13
Number of subjects: 157
Study 15781679 — intervention group
Group type: EXPERIMENTAL
Intervention: UV facial photograph and photoaging information
Number of subjects: 146
Study 15781679 — intervention group
Group type: EXPERIMENTAL
Intervention: UV facial photograph and photoaging information plus sunless tanning lotion
Number of subjects: 146
Study 15781679 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 146
Study 12634948 — intervention group
Group type: EXPERIMENTAL
Intervention: Urate oxidase prophylaxis (period 3)
Number of subjects: 1791
Study 12634948 — intervention group
Group type: COMPARATOR
Intervention: No urate oxidase (period 1)
Number of subjects: 1791
Study 12634948 — intervention group
Group type: EXPERIMENTAL
Intervention: Urate oxidase therapeutic use (period 2)
Number of subjects: 1791
Study 12634948 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐ALL (period 3)
Number of subjects: 1791
Study 10505829 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated digital imaging with objective, automated, computerized image analysis
Number of subjects: 206
Study 10505829 — intervention group
Group type: COMPARATOR
Intervention: Masked review of a complete pediatric ophthalmic exam
Number of subjects: 206
Study 8734859 — intervention group
Group type: EXPERIMENTAL
Intervention: IV adenosine-triphosphate (ATP) 10 or 20mg
Number of subjects: 50
Study 8734859 — intervention group
Group type: COMPARATOR
Intervention: IV verapamil up to 15mg
Number of subjects: 50
Study 1882903 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 70
Study 1882903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 7116051 — intervention group
Group type: EXPERIMENTAL
Intervention: Social intervention (education about schizophrenia, group for relatives, family sessions for relatives and patients)
Number of subjects: 24
Study 7116051 — intervention group
Group type: COMPARATOR
Intervention: Routine out‐patient care (Control group)
Number of subjects: 24
Study 7116051 — intervention group
Group type: EXPERIMENTAL
Intervention: Social intervention
Number of subjects: 24
Study 31119418 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated reading of PET/CT and MRI
Number of subjects: 201
Study 28864226 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP with Mg (2.5mg/kg CDDP, 40mg/kg MgSO4)
Number of subjects: 0